T
Todd E. DeFor
Researcher at University of Minnesota
Publications - 297
Citations - 19625
Todd E. DeFor is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 288 publications receiving 17856 citations. Previous affiliations of Todd E. DeFor include City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Jeffrey S. Miller,Yvette Soignier,Angela Panoskaltsis-Mortari,Sarah A. McNearney,Gong H. Yun,Susan K. Fautsch,David H. McKenna,Chap T. Le,Todd E. DeFor,Linda J. Burns,Paul J. Orchard,Bruce R. Blazar,John E. Wagner,Arne Slungaard,Daniel J. Weisdorf,Ian J. Okazaki,Philip B. McGlave +16 more
TL;DR: It is suggested that haploidentical NK cells can persist and expand in vivo and may have a role in the treatment of selected malignancies used alone or as an adjunct to HCT.
Journal ArticleDOI
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
John E. Wagner,Juliet N. Barker,Todd E. DeFor,K. Scott Baker,Bruce R. Blazar,Cindy R. Eide,Anne I. Goldman,John H. Kersey,William Krivit,Margaret L. MacMillan,Paul J. Orchard,Charles Peters,Daniel J. Weisdorf,Norma K.C. Ramsay,Stella M. Davies +14 more
TL;DR: There is a high probability of survival in recipients of UCB grafts that are disparate in no more than 2 human leukocyte antigens when the grafts contain at least 1.7 x 10(5) CD34(+) cells per kilogram of recipient's body weight, and graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less.
Journal ArticleDOI
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.
Claudio G. Brunstein,Jeffrey S. Miller,Qing Cao,David H. McKenna,Keli L. Hippen,Julie M. Curtsinger,Todd E. DeFor,Bruce L. Levine,Carl H. June,Pablo Rubinstein,Philip B. McGlave,Bruce R. Blazar,John E. Wagner +12 more
TL;DR: There was a reduced incidence of grade II-IV aGVHD with no deleterious effect on risks of infection, relapse, or early mortality and the results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGV HD.
Journal ArticleDOI
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
Juliet N. Barker,Daniel J. Weisdorf,Todd E. DeFor,Bruce R. Blazar,Philip B. McGlave,Jeffrey S. Miller,Catherine M. Verfaillie,John E. Wagner +7 more
TL;DR: Patients with high-risk hematologic malignancy received 2 partially HLA-matched UCB units and disease-free survival was 57% at 1 year, with 72% of patients alive if they received transplants while in remission.
Journal ArticleDOI
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
Claudio G. Brunstein,Juliet N. Barker,Daniel J. Weisdorf,Todd E. DeFor,Jeffrey S. Miller,Bruce R. Blazar,Philip B. McGlave,John E. Wagner +7 more
TL;DR: The use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients, is supported.